No recent analyst price targets found for DNL.
Latest News for DNL
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics' Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)
SOUTH SAN FRANCISCO, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced the publication of results from the open-label Phase 1/2 clinical trial of its investigational, next-generation enzyme replacement therapy (ERT), tividenofusp alfa (DNL310), for the treatment of Hunter syndrome (mucopolysaccharidosis type II, or MPS II) in the January 1, 2026 issue of The New…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for DNL.
Senate Trading
No Senate trades found for DNL.
U.S. House Trading
No House trades found for DNL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.